Less than a tenth of individuals who could benefit from GLP-1 drugs including Wegovy have access to them, caution the World Health Organization as it issues its initial advice on the therapies.
Given in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is urging increased and just availability to these injectable treatments.
Per forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken.
"Our latest guidelines acknowledges that excess weight is a lifelong illness that can be treated with holistic and ongoing support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and logistical bottlenecks are key hurdles to broad availability to the jabs that can help people shift substantial body mass, says the agency.
Skinny Jab Supply Crisis
Even under the present most optimistic scenario, the manufacturing of such drugs could only cover about 100 million people – under 10% of eligible patients, according to the health organization.
The advice urges governments and firms to increase access, through strategies like voluntary licensing.
Exclusive production rights on the active ingredient – the main ingredient of a leading brand – is set to lapse in a number of countries in 2026.
The Way Obesity Injections Operate
The injections imitate a body's own hormone to reduce digestion speed, suppress the appetite and increase satiety so individuals consume fewer calories.
Individuals typically start to lose weight after several weeks of beginning the once-weekly jabs.
Evidence suggests people may regain a significant portion a year later of halting the medication, because their normal appetite return.
To be overweight or obese increases your chance for contracting health problems, such as diabetes, cardiovascular issues, brain attack, and specific malignancies.
Obesity impacts individuals in every country and was associated with 3.7 million deaths worldwide in 2024, as per the health agency.
